Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 14/20 | 0.77 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151554 | 0.91 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| SCHEMBL8151553 | 0.91 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL23833504 | 0.87 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL5444493 | 0.87 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL16115063 | 0.87 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL61222 | 0.87 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL9782857 | 0.87 | SRD5A2 (0.98) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL9782855 | 0.86 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| SCHEMBL9113743 | 0.85 | SRD5A2 (0.68) | SRD5A2SRD5A1 | |
| SCHEMBL8994170 | 0.83 | SRD5A2 (0.69) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844599-B2 | Nitric oxide releasing produgs of therapeutic agents | SATYAM APPARAO (IN) | 2017-12-19 | — | — | US | disclosed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | SRD5A2 2121/4885SRD5A1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.